Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Overland Park, Kansas 66212


Purpose:

The primary objective of this study is to determine if there are significant interactions between oral lorcaserin treatment concurrent with 20 and 40 mg intravenous (i.v.) cocaine infusions by measuring adverse events (AEs) and cardiovascular responses including heart rate (HR), blood pressure (BP), and electrocardiogram (ECG) (including QTc).


Criteria:

Inclusion Criteria: - Be volunteers who are not seeking treatment for drug addiction. - Be between 18 and 50 years-of-age. - Meet Diagnostic and Statistical Manual (DSM-IV) - Text Revision (TR) criteria for current cocaine abuse as assessed using the MINI neuropsychiatric interview (version 6.0). - Have a body mass index (BMI) within a range of 18.0 to 34.0 kg/m2 and a minimum weight of at least 50.0 kg at screening. - Have experience using cocaine by the smoked or i.v. route at least 6 times in the past 12 months prior to clinic intake (Day -3) and at least one use within the past 30 days. - Provide a urine sample positive for cocaine at least once during screening (Days -28 to -4). - Be able to verbalize understanding of consent form, able to provide written informed consent, and verbalize willingness to complete study procedures. - Females must have a negative serum pregnancy test at screening and negative urine pregnancy test at intake prior to receiving the first dose of investigational drug. They must also be postmenopausal, have had a hysterectomy, been sterilized, have a partner with a vasectomy, or agree to use one of the following methods of birth control starting at least 14 days prior to clinic intake: 1. diaphragm and condom by partner 2. condom and spermicide by partner 3. intrauterine device and condom by partner 4. sponge and condom by partner 5. complete abstinence from sexual intercourse 6. oral contraceptives, Depo-Provera, Norplant, Patch, and intrauterine progesterone contraceptive - Be able to comply with protocol requirements, rules and regulations of the study site and be likely to complete all the study treatments. Exclusion Criteria: - Please contact site directly for more information


NCT ID:

NCT02393599


Primary Contact:

Principal Investigator
Debra Kelsh, Ph.D.
Vince & Associates Clinical Research, Inc.


Backup Contact:

N/A


Location Contact:

Overland Park, Kansas 66212
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.